Weigang Wang1,2,3, Baoguo Tian1,2,3, Xiaoqin Xu1,2,3, Xiaofang Zhang1,2,3, Yan Wang1,2,3, Lili Du1,2,3, Jiexian Jing4,5,6. 1. Department of Etiology and Tumor Marker Laboratory, Shanxi Province Cancer Hospital, Taiyuan, 3# Zhigongxin street, Xinghualing District, 030013, Shanxi, People's Republic of China. 2. Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Taiyuan, Shanxi, People's Republic of China. 3. Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. 4. Department of Etiology and Tumor Marker Laboratory, Shanxi Province Cancer Hospital, Taiyuan, 3# Zhigongxin street, Xinghualing District, 030013, Shanxi, People's Republic of China. 2912972872@qq.com. 5. Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Taiyuan, Shanxi, People's Republic of China. 2912972872@qq.com. 6. Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. 2912972872@qq.com.
Abstract
PURPOSE: This research aims to characterize the differences in clinical features and prognostic factors between younger and older breast cancer (BC) patients in China. METHODS: All patients who were recently diagnosed with BC between January 1, 2015 and December 31, 2016 at Shanxi Province Cancer Hospital were recruited. We collected the epidemiological and clinical data as well as the follow-up information. RESULTS: Out of the 1968 BC patients who met the criteria for analysis, 227 (11.53%) were under 40 years of age with a median age of 34 years at diagnosis. All patients were classified into the age < 40, age 40-59, and age ≥ 60 groups. There were significant differences in the histology, tumor size, T stage, grade, and human epidermal growth factor receptor-2 (HER-2) levels among the three groups (all P < 0.05). The 5-year overall survival (OS) rates were 86.34%, 89.58%, and 84.84% for the age < 40, age 40-59, and age ≥ 60 groups, respectively. The TNM stage was the only predictor of clinical outcome in all BC patients. The prognostic value of intrinsic subtypes for OS was different among the three groups. CONCLUSION: Our study helped identify an age-related prognostic indicator of adverse events in BC patients and showed that young women with BC exhibited more aggressive clinical and pathological features. Our findings may facilitate clinical management and therapeutic interventions in young BC patients, especially in young women with a history of exposure to risk factors and age < 40 years.
PURPOSE: This research aims to characterize the differences in clinical features and prognostic factors between younger and older breast cancer (BC) patients in China. METHODS: All patients who were recently diagnosed with BC between January 1, 2015 and December 31, 2016 at Shanxi Province Cancer Hospital were recruited. We collected the epidemiological and clinical data as well as the follow-up information. RESULTS: Out of the 1968 BC patients who met the criteria for analysis, 227 (11.53%) were under 40 years of age with a median age of 34 years at diagnosis. All patients were classified into the age < 40, age 40-59, and age ≥ 60 groups. There were significant differences in the histology, tumor size, T stage, grade, and human epidermal growth factor receptor-2 (HER-2) levels among the three groups (all P < 0.05). The 5-year overall survival (OS) rates were 86.34%, 89.58%, and 84.84% for the age < 40, age 40-59, and age ≥ 60 groups, respectively. The TNM stage was the only predictor of clinical outcome in all BC patients. The prognostic value of intrinsic subtypes for OS was different among the three groups. CONCLUSION: Our study helped identify an age-related prognostic indicator of adverse events in BC patients and showed that young women with BC exhibited more aggressive clinical and pathological features. Our findings may facilitate clinical management and therapeutic interventions in young BC patients, especially in young women with a history of exposure to risk factors and age < 40 years.
Authors: Rebecca H Johnson; Carey K Anders; Jennifer K Litton; Kathryn J Ruddy; Archie Bleyer Journal: Pediatr Blood Cancer Date: 2018-08-28 Impact factor: 3.167
Authors: Erica T Warner; Graham A Colditz; Julie R Palmer; Ann H Partridge; Bernard A Rosner; Rulla M Tamimi Journal: Breast Cancer Res Treat Date: 2013-10-18 Impact factor: 4.872